m Open access bot: doi added to citation with #oabot.
|
Adding short description: "Deficiency in intravenous nutrition patients", overriding automatically generated description
|
||
(9 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Deficiency in intravenous nutrition patients}} |
|||
{{Use dmy dates|date=August 2021}} |
{{Use dmy dates|date=August 2021}} |
||
{{Infobox medical condition (new) |
{{Infobox medical condition (new) |
||
Line 23: | Line 24: | ||
| deaths = |
| deaths = |
||
}} |
}} |
||
'''Chromium deficiency''' is described as the consequence of an insufficient dietary intake of the mineral [[chromium]]. Chromium was first proposed as an [[essential element]] for normal glucose metabolism in 1959,<ref>{{cite journal|last1=SCHWARZ|first1=K|last2=MERTZ|first2=W|title=Chromium(III) and the glucose tolerance factor.|journal=Archives of Biochemistry and Biophysics|date=November 1959|volume=85|pages=292–295|pmid=14444068|doi=10.1016/0003-9861(59)90479-5}}</ref> |
'''Chromium deficiency''' is described as the consequence of an insufficient dietary intake of the mineral [[chromium]]. Chromium was first proposed as an [[essential element]] for normal glucose metabolism in 1959,<ref>{{cite journal|last1=SCHWARZ|first1=K|last2=MERTZ|first2=W|title=Chromium(III) and the glucose tolerance factor.|journal=Archives of Biochemistry and Biophysics|date=November 1959|volume=85|pages=292–295|pmid=14444068|doi=10.1016/0003-9861(59)90479-5}}</ref> but its biological function has not been identified.<ref>{{cite journal|last1=Mertz|first1=W|title=Chromium in human nutrition: a review.|journal=The Journal of Nutrition|date=April 1993|volume=123|issue=4|pages=626–633|pmid=8463863|doi=10.1093/jn/123.4.626|doi-access=free}}</ref> Cases of deficiency were described in people who [[Parenteral nutrition|received all of their nutrition intravenously]] for long periods of time.<ref name=Expert>{{cite web|title=Review of Chromium |date=August 2002 |url=http://www.food.gov.uk/multimedia/pdfs/reviewofchrome.pdf |accessdate=24 February 2013 |author=Expert group on Vitamins and Minerals |url-status=dead |archive-url=https://web.archive.org/web/20120207123911/http://www.food.gov.uk/multimedia/pdfs/reviewofchrome.pdf |archive-date=7 February 2012 }}</ref> |
||
The essentiality of chromium has been challenged.<ref name=Vincent>{{cite journal|last=Vincent|first=John B.|title=Chromium: celebrating 50 years as an essential element?|journal=Dalton Transactions|year=2010|volume=39|issue=16|pages=3787–3794|doi=10.1039/B920480F|pmid=20372701}}</ref><ref>{{cite journal |doi=10.1111/j.1753-4887.1999.tb06909.x |last=Jeejeebhoy |first=Khursheed N. |title=The role of chromium in nutrition and therapeutics and as a potential toxin |journal=Nutrition Reviews |volume=57 |issue=11 |pages=329–335 |year=1999 |pmid=10628183|doi-access=free }}</ref><ref name=Vincent2>{{cite book|last1=Vincent|first1=JB| |
The essentiality of chromium has been challenged.<ref name=Vincent>{{cite journal|last=Vincent|first=John B.|title=Chromium: celebrating 50 years as an essential element?|journal=Dalton Transactions|year=2010|volume=39|issue=16|pages=3787–3794|doi=10.1039/B920480F|pmid=20372701}}</ref><ref>{{cite journal |doi=10.1111/j.1753-4887.1999.tb06909.x |last=Jeejeebhoy |first=Khursheed N. |title=The role of chromium in nutrition and therapeutics and as a potential toxin |journal=Nutrition Reviews |volume=57 |issue=11 |pages=329–335 |year=1999 |pmid=10628183|doi-access=free }}</ref><ref name=Vincent2>{{cite book|last1=Vincent|first1=JB|chapter=Chromium: Is It Essential, Pharmacologically Relevant, or Toxic? |title=Interrelations between Essential Metal Ions and Human Diseases|year=2013|volume=13|pages=171–198|pmid=24470092|doi=10.1007/978-94-007-7500-8_6|isbn=978-94-007-7499-5|series=Metal Ions in Life Sciences}}</ref> Whereas the authorities in the European Union do not recognize chromium as an essential nutrient,<ref name="EFSA" /> those in the United States do, and identify an adequate intake for adults as between 25 and 45 μg/day, depending on age and sex.<ref name=ChromiumDRI/> [[Dietary supplement]]s containing chromium are widely available in the United States, with claims for benefits for fasting plasma glucose, hemoglobin A1C and weight loss. Reviews report the changes as modest, and without scientific consensus that the changes have a clinically relevant impact.<ref name=Costello2016/><ref name=Onakpoya2013>{{cite journal |vauthors=Onakpoya I, Posadzki P, Ernst E |title=Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials |journal=Obes Rev |volume=14 |issue=6 |pages=496–507 |date=2013 |pmid=23495911 |doi=10.1111/obr.12026 |s2cid=21832321 }}</ref> |
||
==Signs and symptoms== |
==Signs and symptoms== |
||
Line 36: | Line 37: | ||
The U.S. Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for chromium in 2001. For chromium there was not sufficient information to set EARs and RDAs, so needs are described as estimates for Adequate Intakes (AIs). The current AIs for chromium for women ages 14 and up is 25 μg/day up to age 50 and 20 μg/day for older. AI for pregnancy is 30 μg/day. AI for lactation is 45 μg/day. For men ages 14 and up 35 μg/day up to age 50 and 30 μg/day for older. For infants to children ages 1–13 years the AI increases with age from 0.2 to 25 μg/day. As for safety, the IOM sets [[Tolerable upper intake level]]s (ULs) for vitamins and minerals when evidence is sufficient. In the case of chromium there is not yet enough information and hence no UL. Collectively the EARs, RDAs, AIs and ULs are referred to as [[Dietary Reference Intake]]s (DRIs).<ref name=ChromiumDRI>Chromium. IN: [https://www.ncbi.nlm.nih.gov/books/NBK222329/ Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Chromium, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Chromium] National Academy Press. 2001, pp. 197-223.</ref> |
The U.S. Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for chromium in 2001. For chromium there was not sufficient information to set EARs and RDAs, so needs are described as estimates for Adequate Intakes (AIs). The current AIs for chromium for women ages 14 and up is 25 μg/day up to age 50 and 20 μg/day for older. AI for pregnancy is 30 μg/day. AI for lactation is 45 μg/day. For men ages 14 and up 35 μg/day up to age 50 and 30 μg/day for older. For infants to children ages 1–13 years the AI increases with age from 0.2 to 25 μg/day. As for safety, the IOM sets [[Tolerable upper intake level]]s (ULs) for vitamins and minerals when evidence is sufficient. In the case of chromium there is not yet enough information and hence no UL. Collectively the EARs, RDAs, AIs and ULs are referred to as [[Dietary Reference Intake]]s (DRIs).<ref name=ChromiumDRI>Chromium. IN: [https://www.ncbi.nlm.nih.gov/books/NBK222329/ Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Chromium, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Chromium] National Academy Press. 2001, pp. 197-223.</ref> |
||
Japan |
Japan designates chromium as an essential nutrient, identifying 10 μg/day as an adequate intake for adults.<ref name=Japan>[http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/Overview.pdf Overview of Dietary Reference Intakes for Japanese (2015)]</ref> |
||
The [[European Food Safety Authority]] (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL defined the same as in United States. The EFSA does not consider chromium to be an essential nutrient, and so has not set PRIs, AIs or ULs. Chromium is the only mineral for which the United States and the European Union disagree on essentiality.<ref name="EFSA">{{cite web | title = Overview on Dietary Reference Values for the EU population as derived by the EFSA Panel on Dietetic Products, Nutrition and Allergies| year = 2017| url = https://www.efsa.europa.eu/sites/default/files/assets/DRV_Summary_tables_jan_17.pdf}}</ref><ref>{{citation| title = Tolerable Upper Intake Levels For Vitamins And Minerals| publisher = European Food Safety Authority| year = 2006| url = http://www.efsa.europa.eu/sites/default/files/efsa_rep/blobserver_assets/ndatolerableuil.pdf}}</ref> |
The [[European Food Safety Authority]] (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL defined the same as in United States. The EFSA does not consider chromium to be an essential nutrient, and so has not set PRIs, AIs or ULs. Chromium is the only mineral for which the United States and the European Union disagree on essentiality.<ref name="EFSA">{{cite web | title = Overview on Dietary Reference Values for the EU population as derived by the EFSA Panel on Dietetic Products, Nutrition and Allergies| year = 2017| url = https://www.efsa.europa.eu/sites/default/files/assets/DRV_Summary_tables_jan_17.pdf}}</ref><ref>{{citation| title = Tolerable Upper Intake Levels For Vitamins And Minerals| publisher = European Food Safety Authority| year = 2006| url = http://www.efsa.europa.eu/sites/default/files/efsa_rep/blobserver_assets/ndatolerableuil.pdf}}</ref> |
||
Line 46: | Line 47: | ||
==Diabetes== |
==Diabetes== |
||
|
Little strong evidence exists that chromium supplementation benefits people who have type 2 diabetes. One meta-analysis reported a statistically significant decrease in fasting [[plasma glucose]] levels (FPG) and a non-significant trend in lower [[Glycated hemoglobin|hemoglobin A1C]] (HbA1C).<ref name=Mauro2016>{{cite journal |vauthors=San Mauro-Martin I, Ruiz-León AM, et al.|title=[Chromium supplementation in patients with type 2 diabetes and high risk of type 2 diabetes: a meta-analysis of randomized controlled trials] |language=es|journal=Nutr Hosp |volume=33 |issue=1 |pages=27 |date=2016 |pmid=27019254 |doi= 10.20960/nh.27|doi-access=free |url=https://www.redalyc.org/pdf/3092/309245772026.pdf }}</ref> A second reported the same,<ref name=Abdoll2013>{{cite journal |vauthors=Abdollahi M, Farshchi A, Nikfar S, Seyedifar M |title=Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials |journal=J Pharm Pharm Sci |volume=16 |issue=1 |pages=99–114 |date=2013 |pmid=23683609 |doi= 10.18433/j3g022|doi-access=free |url=http://pdfs.semanticscholar.org/40c6/0770c72b2d49c52548eef13cf3b4e2f031ea.pdf }}</ref> a third reported significant decreases for both measures,<ref name=Suk2014>{{cite journal |vauthors=Suksomboon N, Poolsup N, Yuwanakorn A |title=Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes |journal=J Clin Pharm Ther |volume=39 |issue=3 |pages=292–306 |date=2014 |pmid=24635480 |doi=10.1111/jcpt.12147 |s2cid=22326435 |doi-access=free }}</ref> while a fourth reported no benefit for either.<ref>{{cite journal |vauthors=Bailey CH |title=Improved meta-analytic methods show no effect of chromium supplements on fasting glucose |journal=Biol Trace Elem Res |volume=157 |issue=1 |pages=1–8 |date=January 2014 |pmid=24293356 |doi=10.1007/s12011-013-9863-9 |s2cid=2441511 }}</ref> A review published in 2016 listed 53 [[randomized clinical trial]]s that were included in one or more of six [[meta-analysis|meta-analyses]]. It concluded that whereas there may be modest decreases in FPG and/or HbA1C that achieve statistical significance in some of these meta-analyses, few of the trials achieved decreases large enough to be expected to be relevant to clinical outcome. The authors also mentioned that trial design was for chromium as an addition to standard glycemic control medications, and so did not evaluate chromium as a first treatment for type 2 diabetes, or for prevention of progression from pre-diabetes to diabetes. The conclusion was that "...there is still little reason to recommend chromium dietary supplements to achieve clinically meaningful improvements in glycemic control."<ref name=Costello2016>{{cite journal |vauthors=Costello RB, Dwyer JT, Bailey RL |title=Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness |journal=Nutr. Rev. |volume=74 |issue=7 |pages=455–468 |date=2016 |pmid=27261273 |doi=10.1093/nutrit/nuw011 |pmc=5009459 }}</ref> The American Diabetes Association publishes a standards of care review every year. The 2018 review makes no mention of chromium supplementation as a possible treatment.<ref>[https://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf Standards of Medical Care for Diabetes - 2018] Diabetes Care 2008:41:Supplement 1.</ref> |
||
==Supplementation== |
==Supplementation== |
||
Chromium supplementation in general is subject to a certain amount of controversy as it is by no means clear that chromium is an essential element in human biology.<ref>{{cite book |last1=Maret|first1=Wolfgang |editor1-last=Sigel|editor1-first=Astrid|editor2-last=Freisinger|editor2-first=Eva|editor3-last=Sigel|editor3-first=Roland K. O. |editor4-last=Carver|editor4-first=Peggy L. (Guest editor) |title=Essential Metals in Medicine:Therapeutic Use and Toxicity of Metal Ions in the Clinic|journal=Metal Ions in Life Sciences |volume=19 |date=2019 |publisher=de Gruyter GmbH|location=Berlin|isbn=978-3-11-052691-2|doi=10.1515/9783110527872-015|pmid=30855110|pages=231–251|chapter=Chapter 9. Chromium Supplementation in Human Health, Metabolic Syndrome, and Diabetes}}</ref> Nevertheless, chromium is an ingredient in [[total parenteral nutrition]], along with other trace minerals.<ref name=Stehle2016/> It is also in nutritional products for [[preterm infant]]s.<ref>{{cite journal|pmid=25527182|year=2015|last1=Finch|first1=C. W|title=Review of trace mineral requirements for preterm infants: What are the current recommendations for clinical practice?|journal=Nutrition in Clinical Practice|volume=30|issue=1|pages=44–58|doi=10.1177/0884533614563353|citeseerx=10.1.1.957.4763}}</ref> Many chromium-containing products, including [[chromium chloride]], [[chromium citrate]], [[chromium(III) picolinate]], [[Chromium polynicotinate|chromium(III) polynicotinate]] are sold as non-prescription dietary supplements.<ref name=ods>{{cite web | url=https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/#h2 | title=Chromium | publisher=Office of Dietary Supplements, US National Institutes of Health | date=2016 | accessdate=26 June 2016}}</ref> |
Chromium supplementation in general is subject to a certain amount of controversy as it is by no means clear that chromium is an essential element in human biology.<ref>{{cite book |last1=Maret|first1=Wolfgang |editor1-last=Sigel|editor1-first=Astrid|editor2-last=Freisinger|editor2-first=Eva|editor3-last=Sigel|editor3-first=Roland K. O. |editor4-last=Carver|editor4-first=Peggy L. (Guest editor) |title=Essential Metals in Medicine:Therapeutic Use and Toxicity of Metal Ions in the Clinic|journal=Metal Ions in Life Sciences |volume=19 |date=2019 |publisher=de Gruyter GmbH|location=Berlin|isbn=978-3-11-052691-2|doi=10.1515/9783110527872-015|pmid=30855110|pages=231–251|chapter=Chapter 9. Chromium Supplementation in Human Health, Metabolic Syndrome, and Diabetes}}</ref> Nevertheless, chromium is an ingredient in [[total parenteral nutrition]], along with other trace minerals.<ref name=Stehle2016>{{cite journal |vauthors=Stehle P, Stoffel-Wagner B, Kuhn KS |title=Parenteral trace element provision: recent clinical research and practical conclusions |journal=Eur J Clin Nutr |volume=70 |issue=8 |pages=886–893 |date=2016 |pmid=27049031 |pmc=5399133 |doi=10.1038/ejcn.2016.53 }}</ref> It is also in nutritional products for [[preterm infant]]s.<ref>{{cite journal|pmid=25527182|year=2015|last1=Finch|first1=C. W|title=Review of trace mineral requirements for preterm infants: What are the current recommendations for clinical practice?|journal=Nutrition in Clinical Practice|volume=30|issue=1|pages=44–58|doi=10.1177/0884533614563353|citeseerx=10.1.1.957.4763}}</ref> Many chromium-containing products, including [[chromium chloride]], [[chromium citrate]], [[chromium(III) picolinate]], [[Chromium polynicotinate|chromium(III) polynicotinate]] are sold as non-prescription dietary supplements.<ref name=ods>{{cite web | url=https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/#h2 | title=Chromium | publisher=Office of Dietary Supplements, US National Institutes of Health | date=2016 | accessdate=26 June 2016}}</ref> |
||
=== Government-approved health claims === |
=== Government-approved health claims === |
Chromium deficiency | |
---|---|
Chromium | |
Specialty | Endocrinology |
Chromium deficiency is described as the consequence of an insufficient dietary intake of the mineral chromium. Chromium was first proposed as an essential element for normal glucose metabolism in 1959,[1] but its biological function has not been identified.[2] Cases of deficiency were described in people who received all of their nutrition intravenously for long periods of time.[3]
The essentiality of chromium has been challenged.[4][5][6] Whereas the authorities in the European Union do not recognize chromium as an essential nutrient,[7] those in the United States do, and identify an adequate intake for adults as between 25 and 45 μg/day, depending on age and sex.[8] Dietary supplements containing chromium are widely available in the United States, with claims for benefits for fasting plasma glucose, hemoglobin A1C and weight loss. Reviews report the changes as modest, and without scientific consensus that the changes have a clinically relevant impact.[9][10]
The claimed symptoms of chromium deficiency caused by long-term total parenteral nutrition are severely impaired glucose tolerance, weight loss, peripheral neuropathy and confusion.[11][8]
According to the Dietary Reference Intake review, neither plasma nor urine concentrations can serve as useful clinical indicators of chromium status. Before chromium became a standard ingredient in total parenteral nutrition (TPN), people receiving TPN as their sole source of nutrition developed symptoms that were reversed within two weeks of chromium being added.[8]
The U.S. Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for chromium in 2001. For chromium there was not sufficient information to set EARs and RDAs, so needs are described as estimates for Adequate Intakes (AIs). The current AIs for chromium for women ages 14 and up is 25 μg/day up to age 50 and 20 μg/day for older. AI for pregnancy is 30 μg/day. AI for lactation is 45 μg/day. For men ages 14 and up 35 μg/day up to age 50 and 30 μg/day for older. For infants to children ages 1–13 years the AI increases with age from 0.2 to 25 μg/day. As for safety, the IOM sets Tolerable upper intake levels (ULs) for vitamins and minerals when evidence is sufficient. In the case of chromium there is not yet enough information and hence no UL. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs).[8]
Japan designates chromium as an essential nutrient, identifying 10 μg/day as an adequate intake for adults.[12]
The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL defined the same as in United States. The EFSA does not consider chromium to be an essential nutrient, and so has not set PRIs, AIs or ULs. Chromium is the only mineral for which the United States and the European Union disagree on essentiality.[7][13]
For U.S. food and dietary supplement labeling purposes the amount in a serving is expressed as a percent of Daily Value (%DV). For chromium labeling purposes 100% of the Daily Value was 120 μg, but as of 27 May 2016 it was revised to 35 μg to bring it into agreement with the RDA.[14][15] Compliance with the updated labeling regulations was required by 1 January 2020, for manufacturers with $10 million or more in annual food sales, and by 1 January 2021 for manufacturers with less than $10 million in annual food sales.[16][17][18] During the first six months following the 1 January 2020 compliance date, the FDA plans to work cooperatively with manufacturers to meet the new Nutrition Facts label requirements and will not focus on enforcement actions regarding these requirements during that time.[16] A table of the old and new adult Daily Values is provided at Reference Daily Intake.
Approximately 2% of ingested chromium(III) is absorbed, with the remainder being excreted in the feces. Amino acids, vitamin C and niacin may enhance the uptake of chromium from the intestinal tract.[19] After absorption, this metal accumulates in the liver, bone, and spleen. Trivalent chromium is found in a wide range of foods, including whole-grain products, processed meats, high-bran breakfast cereals, coffee, nuts, green beans, broccoli, spices, and some brands of wine and beer.[19] Most fruits and vegetables and dairy products contain only low amounts.[3]
Little strong evidence exists that chromium supplementation benefits people who have type 2 diabetes. One meta-analysis reported a statistically significant decrease in fasting plasma glucose levels (FPG) and a non-significant trend in lower hemoglobin A1C (HbA1C).[20] A second reported the same,[21] a third reported significant decreases for both measures,[22] while a fourth reported no benefit for either.[23] A review published in 2016 listed 53 randomized clinical trials that were included in one or more of six meta-analyses. It concluded that whereas there may be modest decreases in FPG and/or HbA1C that achieve statistical significance in some of these meta-analyses, few of the trials achieved decreases large enough to be expected to be relevant to clinical outcome. The authors also mentioned that trial design was for chromium as an addition to standard glycemic control medications, and so did not evaluate chromium as a first treatment for type 2 diabetes, or for prevention of progression from pre-diabetes to diabetes. The conclusion was that "...there is still little reason to recommend chromium dietary supplements to achieve clinically meaningful improvements in glycemic control."[9] The American Diabetes Association publishes a standards of care review every year. The 2018 review makes no mention of chromium supplementation as a possible treatment.[24]
Chromium supplementation in general is subject to a certain amount of controversy as it is by no means clear that chromium is an essential element in human biology.[25] Nevertheless, chromium is an ingredient in total parenteral nutrition, along with other trace minerals.[26] It is also in nutritional products for preterm infants.[27] Many chromium-containing products, including chromium chloride, chromium citrate, chromium(III) picolinate, chromium(III) polynicotinate are sold as non-prescription dietary supplements.[28]
In 2005, the U.S. Food and Drug Administration approved a Qualified Health Claim for chromium picolinate with a requirement for very specific label wording: "One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain."[29] In 2010, chromium(III) picolinate was approved by Health Canada to be used in dietary supplements. Approved labeling statements included: "...provides support for healthy glucose metabolism."[30] The European Food Safety Authority (EFSA) approved claims in 2010 that chromium contributed to normal macronutrient metabolism and maintenance of normal blood glucose concentration.[31]
{{cite book}}
: |editor4-first=
has generic name (help); |journal=
ignored (help)
| |||||
---|---|---|---|---|---|
Protein-energy malnutrition |
| ||||
Vitamin deficiency |
| ||||
Mineral deficiency |
| ||||
Growth |
| ||||
General |
|